Vaxcyte Establishes New $500M At-The-Market Offering Program, Replacing Prior Agreement

summarizeSummary

Vaxcyte, Inc. entered into a new At-The-Market (ATM) sales agreement to offer and sell up to $500 million of its common stock, replacing a prior ATM program.

check_boxKey Events

• New At-The-Market (ATM) Program Established

  Vaxcyte, Inc. entered into a sales agreement with Leerink Partners LLC to sell shares of its common stock with an aggregate offering price of up to $500,000,000 from time to time.

• Prior ATM Program Terminated

  The company terminated its previous Open Market Sale Agreement, dated July 1, 2021, with Jefferies LLC. Approximately $270.3 million in common stock was sold under the prior agreement.

• Flexible Capital Access

  The ATM program allows Vaxcyte to raise capital as needed for general corporate purposes, including funding its ongoing clinical development programs, without a fixed offering price.

• Placement Agent Compensation

  Leerink Partners LLC will receive compensation of up to 3.00% of the gross proceeds from the sale of shares through the program.

auto_awesomeAnalysis

Vaxcyte, a clinical-stage vaccine company, has established a new At-The-Market (ATM) equity offering program, allowing it to sell up to $500 million in common stock. This move, concurrent with its Q4/FY25 financial results and 10-K filing, signals a proactive approach to securing capital for its ongoing and future clinical trials, particularly for its lead VAX-31 vaccine. While ATM programs can create an overhang on the stock due to potential dilution, they provide flexible access to capital, which is critical for biotech companies with significant R&D expenses and no commercial products. The termination of the previous ATM, under which $270.3 million was sold, and the launch of a larger program, indicates a continued strategy to fund operations and development through equity raises. Investors should monitor the pace and pricing of future sales under this program.